Partnering & Drug Development
Life science dealmaking is an ongoing process. EBD Group brings together business development execs from pharma, biotech and investment through our partnering events and online community (partnering360).
Biotech Startups: Land and conduct a successful investor meeting
Biotech startup companies face many challenges, but one of the most common is landing and conducting meetings with potential investors. The following are pieces of advice from investors on what...
How can startup companies get noticed by potential investors and partners?
Access the industry's premier life science partnering event, BioPharm America™ in Boston September 26–27, 2017, to connect with strategic partners and get your innovation funded. No other event combin
Where to start: How to gain a foothold in the China biopharmaceutical market
The China pharmaceutical market has come of age. With record breaking investments in innovative companies, support from the CFDA, and new product approvals pending, China has entered a new age as...
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs
Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s Mike Ward how his company can help biotechs and pharma firms cut the cost of Phase I and IIa t
BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets
With the Latin American vaccines market forecast to more than quadruple in size from just over USD 150 million to 2015 to just under USD 700 million in 2020, opportunities abound for both homegrown bu
Tissue regeneration: A vital area within regenerative medicine
Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence and Nancy Dvorin, Executive Editor, In Vivo Cell and gene therapies often get the lion’s...
Bruce Levine is a man you can thank for your future cell therapy
To call Bruce Levine, PhD, an innovator in the cell and gene therapy space is a gross understatement. He is known for his groundbreaking work in the development and use of synthetic immune cells...
BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline
Thomas Zioncheck, global head of business development for neuroscience, ophthalmology, and research tools and technology at Genentech, talks to Scrip about the company's early-stage partnering strateg
BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice
Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug development company. Chief business officer Andrew Mackie tells Scrip more about this transfor
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities
Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 million fund will prosper from the increased understanding of human and
BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment
Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors original
Testimonials highlight opportunities for China cross-border collaboration
ChinaBio® Partnering Forum 2017 meets May 31–June 1 in Zhuhai, China. Don’t miss the abundant opportunities to engage with the global life science community and forge valuable cross-border partnership
Report findings provide insight into technological innovations and trends in drug development
Knect365 Life Sciences has released a report offering unique insights into the awareness, perceptions and implementation of technological innovations in the drug development industry. Based on a...
BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations
Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications. NOX-A12 i
BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies
Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical developm
Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III
Li Chen, PhD, co-founded Hua Medicine (Shanghai) six years ago with Ge Li, PhD, founder of WuXi AppTec. The company soon in-licensed global rights to a GKA treatment for type 2 diabetes from...
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones
Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its US market approval during the recent BIO-Europe Spring partnering conference. Newron, a clin
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs
During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard chats with Scrip about the company's strategy for partnering with pharmas in the cancer drug
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans
During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company's bispecific antibody pipeline and how its candidates are different
BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy
As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's t